Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9782-0
Annals of Surgical Oncology 15:1161-1168 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Zerbi, A.
Right arrow Articles by Di Carlo, V.
PubMed
Right arrow Articles by Zerbi, A.
Right arrow Articles by Di Carlo, V.

Original Article

Pancreatic Metastasis From Renal Cell Carcinoma: Which Patients Benefit From Surgical Resection?

Alessandro Zerbi, MD1, Enrico Ortolano, MD1, Gianpaolo Balzano, MD1, Anna Borri, MD2, Aldo Alberto Beneduce, MD1 and Valerio Di Carlo, MD1

1 Pancreas Unit, Department of Surgery, S. Raffaele Scientific Institute, V. Olgettina 60, 20132, Milan, Italy
2 Department of Oncology, S. Raffaele Scientific Institute, V. Olgettina 60, 20132, Milan, Italy

Correspondence: Address correspondence and reprint requests to: Alessandro Zerbi, MD; E-mail: zerbi.alessandro{at}hsr.it

Background: Pancreas is a possible site of metastases from renal cell carcinoma (RCC). The aim of this study was to define the role of surgery in their treatment.

Methods: We retrospectively analyzed 36 patients with pancreatic metastasis from RCC observed between January 1998 and February 2006. Patients were categorized into three risk groups according to the modified Memorial Sloan-Kettering prognostic factors model.

Results: Resective surgery was performed in 23 patients, as follows: 11 distal pancreatectomy, 5 enucleation, 4 pancreatoduodenectomy, 2 total pancreatectomy, and 1 middle pancreatectomy. No perioperative mortality was observed; the morbidity rate was 47.8%. All patients who underwent resection belonged to the favorable risk group. Surgical resection was excluded in 13 cases because of locally advanced disease (2 cases) or extrapancreatic disease (11 cases); 5 of these patients were at favorable, 7 at intermediate, and 1 at poor risk. In patients undergoing surgery, the 5-year actuarial survival rate was 88%, and median disease-free survival was 44 months. Patients who did not undergo surgery had a 5-year survival rate of 47%, with a median survival time of 27 months (P = .02).

Conclusions: Patients with pancreatic metastases from RCC belonging to a favorable risk group are candidates for resection, even in the presence of another metastatic site or multifocal pancreatic disease.

Key Words: Renal cell carcinoma • Pancreatic metastases • Pancreatic resection • Pancreas






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.